Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas.

Trial Profile

Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms StiL NHL1 study
  • Most Recent Events

    • 06 Jun 2017 Nine-years results of patients with indolent lymphomas (n=447) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 21 Feb 2013 Results published in Lancet.
    • 11 Dec 2012 Results of a subgroup analysis have been presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2012 according to a Mundipharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top